LIXTE BIOTECHNOLOGY HOLDINGS, INC. LIXT
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-9.09
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$6.1M | — | — | $11.0M |
| 2024 | — | -$3.6M | — | — | $827,219 |
| 2023 | — | -$5.1M | — | — | $4.0M |
| 2022 | — | -$6.3M | — | — | $5.2M |
| 2021 | — | -$6.7M | — | — | $4.8M |
| 2020 | — | -$3.3M | — | — | $5.0M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -9.09 (distress)
- Working capital / assets 0.302
- Retained earnings / assets -4.561
- EBIT / assets -0.401
- Equity / liabilities 6.186
Source: SEC EDGAR filings · CIK 0001335105 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.